A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

The PORTAL study will test a new combination of drugs (glofitamab, polatuzumab vedotin and obinutuzumab) in patients with large B-cell lymphoma (LBCL) that has come back (relapsed) or not responded to previous treatment. It will determine how safe and effective the combination of these cancer drugs is in treating LBCL before and after CAR-T cell therapy.

Trial Details

NCT ID
NCT06071871
Phase
PHASE2
Sponsor
University College, London
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Glofitamab
  • Polatuzumab vedotin
  • Obinutuzumab
Locations (sample)
  • London, United Kingdom|51.50853,-0.12574
  • London, United Kingdom|51.50853,-0.12574
  • Manchester, United Kingdom|53.48095,-2.23743
  • Nottingham, United Kingdom|52.9536,-1.15047
  • Oxford, United Kingdom|51.75222,-1.25596

Key Eligibility Criteria

  • Histologically proven CD20+ LBCL (with CD20 positivity at any timepoint) including diffuse large B cell lymphoma, high grade B cell lymphoma with M…
  • Part 1: Relapsed or refractory disease and eligible for CAR T-cell therapy in the UK and in need of systemic bridging in the opinion of the local i…
  • Part 2: Failed to achieve CMR (Deauville score 1-3) on PET scan 1-month post CAR-T or progressed at any point post CAR-T (patients in part 2 may ha…
  • At least one measurable target lesion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →